全文获取类型
收费全文 | 378022篇 |
免费 | 44094篇 |
国内免费 | 3214篇 |
专业分类
耳鼻咽喉 | 7275篇 |
儿科学 | 11128篇 |
妇产科学 | 6788篇 |
基础医学 | 32345篇 |
口腔科学 | 5988篇 |
临床医学 | 49234篇 |
内科学 | 94155篇 |
皮肤病学 | 10445篇 |
神经病学 | 37521篇 |
特种医学 | 16039篇 |
外国民族医学 | 13篇 |
外科学 | 75600篇 |
综合类 | 2793篇 |
现状与发展 | 73篇 |
一般理论 | 178篇 |
预防医学 | 23310篇 |
眼科学 | 8681篇 |
药学 | 16414篇 |
1篇 | |
中国医学 | 325篇 |
肿瘤学 | 27024篇 |
出版年
2024年 | 785篇 |
2023年 | 5813篇 |
2022年 | 3285篇 |
2021年 | 8163篇 |
2020年 | 8651篇 |
2019年 | 7018篇 |
2018年 | 12951篇 |
2017年 | 11282篇 |
2016年 | 12673篇 |
2015年 | 13547篇 |
2014年 | 22864篇 |
2013年 | 25868篇 |
2012年 | 22320篇 |
2011年 | 23081篇 |
2010年 | 19757篇 |
2009年 | 22617篇 |
2008年 | 21257篇 |
2007年 | 20377篇 |
2006年 | 22271篇 |
2005年 | 19560篇 |
2004年 | 17901篇 |
2003年 | 15639篇 |
2002年 | 15140篇 |
2001年 | 5610篇 |
2000年 | 4346篇 |
1999年 | 5138篇 |
1998年 | 6238篇 |
1997年 | 5522篇 |
1996年 | 5121篇 |
1995年 | 4828篇 |
1994年 | 3383篇 |
1993年 | 2990篇 |
1992年 | 2374篇 |
1991年 | 2332篇 |
1990年 | 1850篇 |
1989年 | 1947篇 |
1988年 | 1708篇 |
1987年 | 1519篇 |
1986年 | 1558篇 |
1985年 | 1457篇 |
1984年 | 1472篇 |
1983年 | 1325篇 |
1982年 | 1546篇 |
1981年 | 1371篇 |
1980年 | 1207篇 |
1979年 | 811篇 |
1978年 | 878篇 |
1977年 | 856篇 |
1976年 | 663篇 |
1975年 | 603篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
12.
13.
14.
15.
16.
Hideki Kawaguchi Kazuko Masuo Tomohiro Katsuya Ken Sugimoto Hiromi Rakugi Toshio Ogihara Michael L Tuck 《Hypertension research》2006,29(12):951-959
High blood pressure (BP) is a major determinant of cardiovascular events in obesity. The beta2- and beta3-adrenoceptor polymorphisms are associated with obesity and hypertension. In the present study, we examine the relationships of beta2- and beta3-adrenoceptor polymorphisms with further weight gain-induced BP elevation in obese subjects. Changes in BP, body weight, total body fat-mass, waist-to-hip ratio, plasma norepinephrine (NE) and leptin levels, and beta2(Arg16Gly)- and beta3(Trp64Arg)-adrenoceptor polymorphisms were measured periodically over a 5-year period in 55 entry obese (body mass index [BMI]> or =25.0 kg/m(2)) normotensive (BP<140/90 mmHg) men. BP elevation and weight gain were defined as > or =10% increases from entry levels over 5 years in mean BP or BMI. Obese subjects with weight gain, BP elevation or weight gain-induced BP elevation had higher frequencies of the Gly16 allele of Arg16GIy and Arg64 allele of Trp64Arg. Subjects carrying the Gly16 or Arg64 alleles had significantly greater total fat-mass and waist-to-hip ratio at entry and over a 5-year period compared to the subjects who did not carry these polymorphisms. Subjects carrying the Gly16 allele had similar levels of plasma NE, higher levels of plasma leptin and a lower slope of the regression lines between plasma leptin and NE levels. Those carrying the Arg64 allele had higher plasma NE levels at entry and over a 5-year period compared to the subjects without the Arg64 allele, but plasma leptin levels and slopes were similar. The findings demonstrate that the Arg64 allele of the beta3-adrenoceptor polymorphisms relates to weight gain-induced BP elevation accompanying high plasma NE (heightened sympathetic activity) in obese men. The Gly16 allele of the beta2-adrenoceptor polymorphisms links to weight gain-induced BP elevation associated with leptin resistance. beta2- and beta3-adrenoceptor polymorphisms could predict the future BP elevation and further weight gain-induced BP elevation in originally obese subjects. 相似文献
17.
18.
19.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献
20.